Project Grant R43CA287530
Award Date
8/1/24
Completion Date
7/31/25
Dollars Obligated
$399K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Richmond, VA 23219, USA
Similar Awards
This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.396 Cancer Biology Research program), aims to develop highly effective cancer immunotherapeutic vaccines to address global health disparities in cervical cancer associated with human papillomavirus (HPV) 16 variants. The $630,506 award, spanning 2025-2029, will fund research to: 1) characterize immune evasion by studying presentation of HPV E6/E7 epitope variants across different human MHC-1 alleles; 2) evaluate...
This $131,220 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will support cancer vaccine research under the Cancer Research Manpower federal grant program (CFDA 93.398). The grant recipient, Stanford University, will develop a new approach to cancer vaccination that directly reprograms cancer cells into antigen presenting cells (APCs) through mRNA-enabled cell reprogramming. Researchers aim to overcome barriers to current vaccination...
The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded The Johns Hopkins University a $630,781 Project Grant (R01CA293906) on April 25, 2025 to develop engineered lipid nanoparticle (LNP) and microgel matrix formulations to program Th1/Th2 immune responses for cancer immunotherapy. The key objectives are to: 1) develop mRNA LNP formulations capable of eliciting dual or biased Th1/Th2 immune responses using machine learning; 2) engineer mRNA LNP-loaded microgels as an...
This $1,284,172 Cooperative Agreement award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports a two-center, Phase II clinical trial of E7 TCR-T cell therapy for treating metastatic HPV-associated cancers. The primary goal is to assess the response rate of this novel immunotherapy approach, which leverages engineered autologous T-cells targeting the HPV E7 oncoprotein. The research will be conducted through a collaboration between Rutgers Cancer Institute of...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $577,293 to the Regents of the University of Michigan to develop and test multivalent small circular mRNA (circRNA) vaccines for melanoma combination immunotherapy. The key products and services include: Developing highly stable, modification-free multivalent small circRNA vaccines to elicit potent and durable anti-tumor immunity for immune checkpoint blockade combination therapy in...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $628,499 to the University of California, Los Angeles to develop innovative mRNA vaccines to enhance the efficacy of T-cell transfer therapies against solid tumors, with a focus on pancreatic ductal adenocarcinoma. The research framework includes mechanistic studies to optimize mRNA-encoded antigen and adjuvant properties, evaluate the new vaccines in humanized immune system mouse models,...
The National Cancer Institute (NCI) awarded a $619,294 Project Grant under CFDA 93.394 "Cancer Detection and Diagnosis Research" to the University of California, San Diego (UCSD) to develop slow-release CPMV (Cowpea Mosaic Virus)-polymer blend formulations for intratumoral immunotherapy delivery. The project aims to formulate CPMV-laden slow-release devices, establish and tune the release rates, confirm the structural integrity and biological activity of the released CPMV, and...
The National Cancer Institute (NCI) awarded a $191,700 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Northwestern University to conduct a pilot trial testing four digital intervention components targeting HPV vaccination among the U.S. Vietnamese population. The project, titled "Applying the Multiphase Optimization Strategy to Develop and Test a Culturally-Relevant Digital Health Intervention Targeting HPV Vaccination Among U.S. Vietnamese", aims to assess...
The National Cancer Institute (NCI) awarded a $408,829 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Pittsburgh to develop positive allosteric modulators (PAMs) targeting the XCR1 chemokine receptor. This research aims to enhance the function of conventional dendritic cells type 1 (cDC1s) and cytotoxic T-cell responses within the tumor microenvironment as a novel approach for cancer treatment. The project will utilize DNA-encoded library technology to screen for...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $863,708 to Mirecule, Inc. to develop an antibody-oligonucleotide conjugate therapy for treating head and neck squamous cell carcinoma. The award period runs from September 18, 2024 to August 31, 2026. The key products or services to be delivered under this award include: 1) validating the efficacy of the MC-30 antibody-RNA conjugate in preclinical cancer models, 2) executing...